These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26174236)

  • 21. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
    Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
    Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
    Dobnig H; Stepan JJ; Burr DB; Li J; Michalská D; Sipos A; Petto H; Fahrleitner-Pammer A; Pavo I
    J Bone Miner Res; 2009 Dec; 24(12):1998-2006. PubMed ID: 19453263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R; Wang O; Satterwhite J; Mitlak B
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.
    Dede AD; Trovas G; Chronopoulos E; Triantafyllopoulos IK; Dontas I; Papaioannou N; Tournis S
    Osteoporos Int; 2016 Dec; 27(12):3409-3425. PubMed ID: 27503175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
    Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
    Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Eastell R; Chen P; Saag KG; Burshell AL; Wong M; Warner MR; Krege JH
    Bone; 2010 Apr; 46(4):929-34. PubMed ID: 20060078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The teriparatide in the treatment of severe senile osteoporosis.
    Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
    Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
    Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of teriparatide in sequential and combination therapy of osteoporosis.
    Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
    Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study.
    Cejka D; Kodras K; Bader T; Haas M
    Kidney Blood Press Res; 2010; 33(3):221-6. PubMed ID: 20588059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate.
    Cosman F; Nieves JW; Zion M; Barbuto N; Lindsay R
    J Bone Miner Res; 2009 Jun; 24(6):1110-5. PubMed ID: 19113926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.